Clinical Trial Update: 68Ga-NYM096/177Lu-NYM096 in Metastatic ccRCC [Phase 1]

View source ↗

Summary

A Phase 1 trial of 68Ga-NYM096 and 177Lu-NYM096 for metastatic clear cell renal cell carcinoma is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• 177Lu-NYM096
• 68Ga-NYM096

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Clear Cell Renal Cell Carcinoma | Phase 1 | Status: SUSPENDED